## NIHON KOHDEN CORPORATION (6849)

Stock Exchange Listing:
Head Office:
Representative:
Contact:
$1^{\text {st }}$ section Tokyo Stock Exchange
Tokyo
Kazuo Ogino, President and CEO
Takeshi Akahane, Corporate Director, General Manager, Managing and Planning Dept. Phone: +81 / 3-5996-8003
(URL http://www.nihonkohden.com/)

1. Consolidated Financial Highlights for the 1st Half of FY2007 (From April 1, 2007 to September 30, 2007)

|  | Net sales |  | Operating profit |  | Ordinary profit |  | Net income |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% |
| First half FY2007 | 50,730 | 7.7 | 4,863 | 47.5 | 4,918 | 38.2 | 2,938 | 43.4 |
| First half FY2006 | 47,113 | 15.6 | 3,296 | 32.5 | 3,558 | 27.9 | 2,049 | -5.7 |
| FY2006 | 96,679 |  | 7,973 |  | 8,448 |  | 5,052 |  |


|  | Net income <br> per share- Basic | Net income <br> per share - Diluted |
| :---: | :---: | :---: |
| First half FY2007 | yen | yen |
| First half FY2006 | $\mathbf{6 6 . 7 2}$ | - |
| FY2006 | 46.23 | - |

(Note) Investment income for equity method: First half FY2007:-4 million yen First half FY2006: 18 million yen FY2006: 46 million yen

## (2) Consolidated Financial Conditions

|  | Total assets | Net assets | Equity ratio | Net assets per share |
| :---: | :---: | :---: | :---: | :---: |
| First half FY2007 | Millions of yen | Millions of yen | $\%$ | Yen |
| First half FY2006 | $\mathbf{7 3 , 3 1 0}$ | $\mathbf{5 1 , 0 1 0}$ | $\mathbf{6 9 . 1}$ | $\mathbf{1 , 1 5 0 . 0 4}$ |
| FY2006 | 72,274 | 47,211 | 64.9 | $1,057.93$ |

(Note) Equity: $\quad$ First half FY2007: 50,644 million yen First half FY2006: 46,892 million yen FY2006: 48,503 million yen
(3) Consolidated Cash Flows

|  | Cash flows from <br> operating activities | Cash flows from <br> investing activities | Cash flows from <br> financing activities | Cash and cash equivalents, end <br> of the period |
| :---: | :---: | :---: | :---: | :---: |
| First half FY2007 | Millions of yen | Millions of yen | Millions of yen | Millions of yen |
| First half FY2006 | $\mathbf{5 , 0 2 1}$ | $\mathbf{- 1 , 0 7 3}$ | $\mathbf{- 1 , 5 6 7}$ | $\mathbf{1 3 , 4 0 3}$ |
| FY2006 | 2,693 | $-1,301$ | -831 | 11,404 |

## 2. Dividends

|  | Dividends per share |  |  |
| :---: | ---: | ---: | ---: |
|  | Interim |  | Year end |
| FY2006 | yen | Total |  |
| FY2007 | 15.00 | 15.00 | yen |
| FY2007 (Forecast) | 17.00 | - | 30.00 |

## 3. Consolidated Forecast for FY2007 (From April 1, 2007 to March 31, 2008)

The company has revised the forecast for FY2007, previously announced on May 18, 2007.

|  | Net sales |  | Operating profit |  | Ordinary profit |  | Net income |  | $\begin{gathered} \text { Net income } \\ \text { per share- Basic } \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% | yen |
| Full year | 102,800 | 6.3 | 9,500 | 19.1 | 9,600 | 13.6 | 6,000 | 18.7 | 136.25 |

[^0]4. Other
(1) Change in Scope of consolidation: None
(2) Changes in Accounting Rules, Procedures, Presentation Method, etc. for the Consolidation Financial Statement: Yes
(3) Number of outstanding shares (Common Stock )

Number of outstanding shares at the end of the period: First half FY2007: 45,765,490 First half FY2006: 45,765,490 FY2006: 45,765,490 Number of treasury stocks: First half FY2007: 1,728,640 First half FY2006: 1,441,173 FY2006: 1,727,745
(Reference) Non-Consolidated Financial Highlights

1. Non-Consolidated Financial Highlights for the 1st Half of FY2007 (From April 1, 2007 to September 30, 2007)


|  | Net income <br> per share- Basic |
| :---: | :---: |
| First half FY2007 | yen |
| First half FY2006 | $\mathbf{6 8 . 6 2}$ |
| FY2006 | 55.47 |

(2) Non-Consolidated Financial Conditions

|  | Total assets | Net assets | Equity ratio | Net assets per share |
| :---: | :---: | :---: | :---: | :---: |
| First half FY2007 | Millions of yen | Millions of yen | $\%$ | Yen |
| First half FY2006 | $\mathbf{6 6 , 7 5 2}$ | $\mathbf{4 6 , 7 1 7}$ | $\mathbf{7 0 . 0}$ | $\mathbf{1 , 0 6 0 . 8 6}$ |
| FY2006 | 66,758 | 43,213 | 64.7 | 974.94 |

(Note) Equity: $\quad$ First half FY2007: 46,717 million yen First half FY2006: 43,213 million yen FY2006: 44,558 million yen
2. Non-Consolidated Forecast for FY2007 (From April 1, 2007 to March 31, 2008)

The company has revised the forecast for FY2007, previously announced on May 18, 2007.

|  | Net sales |  | Operating profit |  | Ordinary profit |  | Net income |  | $\begin{gathered} \text { Net income } \\ \text { per share- Basic } \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% | Millions of yen | \% | yen |
| Full year | 67,000 | 7.7 | 7,600 | 19.0 | 8,400 | 9.4 | 5,500 | 3.6 | 124.90 |

[^1][^2]
## 5. Review of Operations

During the term under review (April 1, 2007 to September 30, 2007), as the Japanese government made progress on National Health Insurance reform, the business environment remained severe for medical equipment suppliers. Outside Japan, competition intensified as western companies expanded their business scale through M\&A as well as the rise of emerging Asian companies. Under these circumstances, to strengthen our organization and business structures, Nihon Kohden has started a new 3-year business plan, SPEED UP II, for the period until FY2009 (ending March 2010).

Japan: Although AED (automated external defibrillators) experienced strong sales growth due to the increased penetration of AEDs in the PAD (public access defibrillation) market, sales in the university market and public hospital market decreased from the first half of prior year when the Company had large-scale orders for information systems. As a result, domestic sales decreased $1.2 \%$ over the first half of FY2006, to $¥ 36,766$ million. Patient Monitors sales increased due to higher sales of bedside monitors and clinical information systems. Sales of Treatment Equipment and Medical Supplies also increased steadily. In Physiological Measuring Equipment, sales of ECG and polygraphs decreased due to sluggish sales of system network products, while EEG sales increased.

International: Sales in North America increased due to solid sales of Patient Monitors. Sales of Patient Monitors and Medical Supplies in Latin America soared mainly due to the shipment of the balance of large-scale orders, which was carried forward from the prior year. Sales in Europe were up with good performance in Patient Monitors, hematology analyzers and Medical Supplies. Sales in China were weak mainly due to lower ECG sales, while sales in other Asian countiries increased with higher sales of Patient Monitors. As a result, international sales increased $41.3 \%$ over the first half of fiscal 2006, to $¥ 13,964$ million.

Overall sales during the term under review increased $7.7 \%$ over the first half of FY2006 to $¥ 50,730$ million. Operating profit, ordinary profit and net profit also increased as a result of higher sales and higher gross profit ratio, primarily due to a favorable product mix with increased sales of our own products. Operating profit increased $47.5 \%$ to $¥ 4,863$ million, ordinary profit increased $38.2 \%$ to $¥ 4,918$ million and net income increased $43.4 \%$ to $¥ 2,938$ million over the first half of prior year.

## 6. Consolidated Sales Results of First half FY2007 by Product Segment

|  | First half FY2007 |  |  | First half FY2006 |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | Growth rate (\%) | $\begin{gathered} \hline \text { Composition } \\ (\%) \\ \hline \end{gathered}$ | Amount | Growth rate (\%) |
| Physiological Measuring Equipment | 7,356 | -10.9 | 14.5 | 8,252 | 23.8 |
| Patient Monitors | 11,276 | 24.4 | 22.2 | 9,065 | 7.3 |
| Treatment Equipment | 7,640 | 12.3 | 15.1 | 6,804 | 25.0 |
| Medical Supplies | 16,453 | 18.4 | 32.4 | 13,897 | 4.1 |
| Other Medical Equipment | 8,003 | -12.0 | 15.8 | 9,094 | 32.9 |
| Total | 50,730 | 7.7 | 100.0 | 47,113 | 15.6 |
| (Reference) Overseas Sales | 13,964 | 41.3 | 27.5 | 9,886 | 9.6 |

## 7. Consolidated Forecast for FY 2007 by Product Segment

|  | (Millions of yen) |  |  |
| :---: | :---: | :---: | :---: |
|  | FY2007 (Forecast) |  |  |
|  | Amount | Growth rate (\%) | $\begin{gathered} \text { Composition } \\ (\%) \\ \hline \end{gathered}$ |
| Physiological Measuring Equipment | 16,500 | 0.1 | 16.1 |
| Patient Monitors | 22,100 | 12.3 | 21.5 |
| Treatment Equipment | 15,300 | 13.4 | 14.9 |
| Medical Supplies | 32,100 | 9.2 | 31.2 |
| Other Medical Equipment | 16,800 | -4.7 | 16.3 |
| Total | 102,800 | 6.3 | 100.0 |
| (Reference) Overseas Sales | 26,100 | 19.0 | 25.4 |

## 8. Consolidated Financial Statements

(1) Consolidated Balance Sheets

| (1) Consolidated Balance Sheets |  |  |  |  | (Milli | of yen) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | First half FY2006 |  | First half FY2007 |  | FY2006 |  |
|  | Amount | \% | Amount | \% | Amount | \% |
| ASSETS |  |  |  |  |  |  |
| Current Assets: |  |  |  |  |  |  |
| Cash | 11,440 |  | 13,413 |  | 11,060 |  |
| Trade notes and accounts receivable | 26,326 |  | 26,192 |  | 28,805 |  |
| Inventories | 14,829 |  | 13,321 |  | 15,008 |  |
| Deferred income taxes | 3,098 |  | 2,818 |  | 3,214 |  |
| Other current assets | 915 |  | 882 |  | 947 |  |
| Allowance for doubtful receivables | -154 |  | -142 |  | -128 |  |
| Total current assets | 56,455 | 78.1 | 56,485 | 77.0 | 58,908 | 77.6 |
| Fixed Assets: |  |  |  |  |  |  |
| Tangible fixed assets: |  |  |  |  |  |  |
| Buildings and structures | 2,981 |  | 3,190 |  | 3,189 |  |
| Machinery, equipment and vehicles | 690 |  | 652 |  | 697 |  |
| Tools, furniture and fixtures | 2,357 |  | 2,596 |  | 2,639 |  |
| Land | 2,499 |  | 2,550 |  | 2,499 |  |
| Construction in progress | 401 |  | 238 |  | 288 |  |
| Total tangible fixed assets | 8,930 | 12.4 | 9,229 | 12.6 | 9,314 | 12.3 |
| Intangible fixed assets | 804 | 1.1 | 1,010 | 1.4 | 1,043 | 1.4 |
| Investments and other assets: |  |  |  |  |  |  |
| Investments in securities | 4,769 |  | 4,616 |  | 4,910 |  |
| Deferred income taxes | 21 |  | 22 |  | 19 |  |
| Prepaid pension expenses | - |  | 888 |  | - |  |
| Other investments and other assets | 1,660 |  | 1,382 |  | 2,064 |  |
| Allowance for doubtful receivables | -366 |  | -325 |  | -366 |  |
| Total investments and other assets | 6,084 | 8.4 | 6,585 | 9.0 | 6,627 | 8.7 |
| Total fixed assets | 15,819 | 21.9 | 16,825 | 23.0 | 16,985 | 22.4 |
| Total Assets | 72,274 | 100.0 | 73,310 | 100.0 | 75,894 | 100.0 |
| LIABILITIES |  |  |  |  |  |  |
| Current Liabilities: |  |  |  |  |  |  |
| Trade notes and accounts payable | 15,921 |  | 13,318 |  | 16,121 |  |
| Short-term debt | 2,840 |  | 1,718 |  | 2,522 |  |
| Other payables | 551 |  | 763 |  | 859 |  |
| Accrued income taxes | 1,326 |  | 1,611 |  | 1,923 |  |
| Accrued expenses | 1,519 |  | 1,675 |  | 1,938 |  |
| Accrued bonuses | 1,464 |  | 1,537 |  | 1,806 |  |
| Accrued bonuses to directors and corporate auditors | - |  | - |  | 77 |  |
| Other current liabilities | 831 |  | 1,147 |  | 1,127 |  |
| Total current liabilities | 24,454 | 33.8 | 21,772 | 29.7 | 26,376 | 34.7 |
| Non-current liabilities: |  |  |  |  |  |  |
| Long-term debt | 137 |  | 40 |  | 111 |  |
| Long-term accounts payable | - |  | 271 |  | - |  |
| Deferred income taxes | 168 |  | 177 |  | 222 |  |
| Liabilities for retirement and severance benefits | 263 |  | - |  | 281 |  |
| Other non-current liabilities | 38 |  | 37 |  | 37 |  |
| Total non-current liabilities | 607 | 0.9 | 527 | 0.7 | 653 | 0.9 |
| Total liabilities | 25,062 | 34.7 | 22,300 | 30.4 | 27,029 | 35.6 |
| NET ASSETS |  |  |  |  |  |  |
| Stockholders' equity: |  |  |  |  |  |  |
| Common stock | 7,544 | 10.4 | 7,544 | 10.3 | 7,544 | 9.9 |
| Additional paid-in capital | 10,485 | 14.5 | 10,485 | 14.3 | 10,485 | 13.8 |
| Retained earnings | 28,364 | 39.3 | 32,987 | 45.0 | 30,709 | 40.5 |
| Treasury stock | -1,017 | -1.4 | -1,757 | -2.4 | -1,755 | -2.3 |
| Total stockholders' equity | 45,376 | 62.8 | 49,259 | 67.2 | 46,983 | 61.9 |
| Valuation and translation adjustments: |  |  |  |  |  |  |
| Net unrealized gain on other securities | 1,563 | 2.2 | 1,267 | 1.7 | 1,468 | 1.9 |
| Deferred gains on hedges | 10 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Foreign currency translation adjustments | -58 | -0.1 | 116 | 0.2 | 49 | 0.1 |
| Total valuation and translation adjustments | 1,515 | 2.1 | 1,384 | 1.9 | 1,519 | 2.0 |
| Minority interests | 319 | 0.4 | 365 | 0.5 | 361 | 0.5 |
| Total Net Assets | 47,211 | 65.3 | 51,010 | 69.6 | 48,864 | 64.4 |
| Total Liabilities and Net Assets | 72,274 | 100.0 | 73,310 | 100.0 | 75,894 | 100.0 |

(2) Consolidated Statements of Income (Summary)
(Millions of yen)

|  | First half FY2006 |  | First half FY2007 |  | FY2006 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% | Amount | \% | Amount | \% |
| Net sales | 47,113 | 100.0 | 50,730 | 100.0 | 96,679 | 100.0 |
| Cost of sales <br> Gross profit | $\begin{array}{r} 24,406 \\ 22,706 \\ \hline \end{array}$ | $\begin{aligned} & 51.8 \\ & 48.2 \end{aligned}$ | $\begin{gathered} 24,880 \\ 25,850 \\ \hline \end{gathered}$ | $\begin{aligned} & 49.0 \\ & 51.0 \end{aligned}$ | 49,246 <br> 47,432 | $\begin{aligned} & 50.9 \\ & 49.1 \\ & \hline \end{aligned}$ |
| Selling, general and administrative expenses Operating profit | $\begin{array}{r} 19,409 \\ \mathbf{3 , 2 9 6} \end{array}$ | $\begin{array}{r} 41.2 \\ 7.0 \\ \hline \end{array}$ | 20,986 <br> 4,863 | $\begin{array}{r} 41.4 \\ 9.6 \\ \hline \end{array}$ | $\begin{array}{r} 39,458 \\ 7,973 \end{array}$ | 40.9 8.2 |
| Non-operating profit <br> Non-operating expenses <br> Ordinary profit | $\begin{array}{r} 353 \\ 92 \\ 3,558 \end{array}$ | $\begin{aligned} & 0.7 \\ & 0.2 \\ & 7.5 \end{aligned}$ | $\begin{gathered} 266 \\ 212 \\ 4,918 \end{gathered}$ | $\begin{gathered} 0.5 \\ 0.4 \\ 9.7 \end{gathered}$ | $\begin{array}{r} 815 \\ 341 \\ \mathbf{8 , 4 4 8} \end{array}$ | 0.8 0.4 $\mathbf{8 . 7}$ |
| Extraordinary profit <br> Extraordinary expenses <br> Income before income taxes and minority interests | $\begin{array}{r} 13 \\ 159 \\ \mathbf{3 , 4 1 1} \end{array}$ | $\begin{aligned} & 0.0 \\ & 0.3 \\ & 7.2 \end{aligned}$ | $\begin{array}{r} 63 \\ - \\ \mathbf{4 , 9 8 1} \end{array}$ | $\begin{aligned} & 0.1 \\ & 0.0 \\ & 9.8 \end{aligned}$ | $\begin{array}{r} 33 \\ 171 \\ \mathbf{8 , 3 1 0} \end{array}$ | 0.1 0.2 $\mathbf{8 . 6}$ |
| Income taxes <br> Minority interests | $1,332$ | $\begin{aligned} & 2.8 \\ & 0.1 \\ & \hline \end{aligned}$ | $\begin{array}{r} 2,021 \\ 21 \\ \hline \end{array}$ | $\begin{aligned} & 4.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $3,202$ | 3.3 0.1 |
| Net income | 2,049 | 4.3 | 2,938 | 5.8 | 5,052 | 5.2 |

(3) Consolidated Statements of Cash Flows
(Millions of yen)

|  | First half FY2006 | First half FY2007 | FY2006 (Summary) |
| :---: | :---: | :---: | :---: |
|  | Amount | Amount | Amount |
| Cash flows from operating activities: <br> Income before income taxes and minority interests Depreciation and amortization <br> Amortization of goodwill <br> Loss on disposal of property, plant and equipment <br> Allowance for doubtful receivables <br> Increase (decrease) in accrued bonuses <br> Increase (decrease) in accrued bonuses to directors and corporate auditors <br> Increase in prepaid pension expenses <br> Increase (decrease) in directors retirement allowances <br> Interest and dividend income <br> Interest expenses <br> Exchange (gain) loss <br> Loss on devaluation of investments in securities <br> Gain on sale of investments in securities <br> Decrease in trade notes and accounts receivable <br> (Increase) decrease in inventories <br> Decrease in trade notes and accounts payable <br> Increase (decrease) in consumption taxes payable <br> Equity in earnings of affiliates <br> Other, net | $\begin{array}{r} 3,411 \\ 742 \\ 74 \\ 15 \\ 18 \\ 396 \\ -217 \\ -2 \\ 8 \\ -36 \\ 29 \\ -19 \\ - \\ - \\ 3,764 \\ -746 \\ -1,429 \\ -80 \\ -18 \\ -935 \end{array}$ | $\begin{array}{r} 4,981 \\ 944 \\ -10 \\ -27 \\ -269 \\ -77 \\ -264 \\ -281 \\ -59 \\ 39 \\ -24 \\ - \\ - \\ 2,891 \\ 1,687 \\ -2,802 \\ 120 \\ 4 \\ 0 \end{array}$ | $\begin{array}{r}8,310 \\ 1,698 \\ 74 \\ 99 \\ -7 \\ 739 \\ 77 \\ -567 \\ 26 \\ -82 \\ 92 \\ 71 \\ 18 \\ -19 \\ 1,599 \\ -926 \\ \hline 1,228 \\ -124 \\ -46 \\ \hline-239\end{array}$ |
| Sub total | 4,980 | 6,874 | 9,565 |
| Interest and dividend received <br> Interest paid <br> Income taxes paid <br> Net cash provided by operating activities | $\begin{array}{r}36 \\ -29 \\ -2,293 \\ \hline 2,693 \\ \hline\end{array}$ | $\begin{array}{r}59 \\ -40 \\ -1,871 \\ \mathbf{5 , 0 2 1} \\ \hline\end{array}$ | $\begin{array}{r}84 \\ -87 \\ -3,680 \\ \mathbf{5 , 8 8 2} \\ \hline\end{array}$ |
| Cash flows from investing activities: <br> Proceeds from sale of investments in securities <br> Purchase of investments in securities <br> Proceeds from sale of property, plant and equipment <br> Capital expenditures <br> Purchase of intangible assets <br> Proceeds from purchases of subsidiary stock due to changing scope of consolidation <br> Other, net <br> Net cash used in investing activities | - 127 <br> 8 <br> - 1,076 <br> - 163 <br> 30 <br> 27 $-1,301$ | $\begin{array}{r} -48 \\ 7 \\ -889 \\ -188 \\ - \\ 45 \\ \hline \mathbf{- 1 , 0 7 3} \\ \hline \end{array}$ | $\begin{array}{r} 60 \\ -461 \\ 9 \\ -2,242 \\ -484 \\ 30 \\ 36 \\ -\mathbf{3 , 0 5 0} \\ \hline \end{array}$ |
| Cash flows from financing activities: <br> Decrease in short-term debt <br> Payments on long-term debt <br> Dividends paid to stockholders <br> Purchase of treasury stock <br> Other, net <br> Net cash used in financing activities | $\begin{array}{r} -208 \\ -16 \\ -575 \\ -3 \\ -28 \\ -831 \end{array}$ | $\begin{array}{r} -795 \\ -70 \\ -660 \\ -2 \\ -38 \\ -\mathbf{1}, 567 \\ \hline \end{array}$ | $\begin{array}{r} -538 \\ -42 \\ -1,238 \\ -740 \\ -31 \\ -2,591 \end{array}$ |
| Effect of exchange rate changes on cash and cash equivalents | 38 | -4 | -17 |
| Net increase in cash and cash equivalents | 599 | 2,375 | 223 |
| Cash and cash equivalents at beginning of year | 10,804 | 11,027 | 10,804 |
| Cash and cash equivalents at end of year | 11,404 | 13,403 | 11,027 |

## 9. Overseas Sales

| First half FY2006 (Millions of yen) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Americas | Europe | Asia | Other | Total |
| Overseas sales | 3,596 | 2,992 | 2,904 | 393 | 9,886 |
| Consolidated sales |  |  |  |  | 47,113 |
| Percentage of overseas sales to consolidated sales(\%) | 7.6 | 6.4 | 6.2 | 0.8 | 21.0 |

## First half FY2007

(Millions of yen)

|  | Americas | Europe | Asia | Other | Total |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Overseas sales | 6,955 | 3,668 | 2,861 | 479 | 13,964 |
| Consolidated sales |  |  |  |  | 50,730 |
| Percentage of overseas sales to <br> consolidated sales (\%) | 13.7 | 7.2 | 5.6 | 0.9 | 27.5 |


| FY2006 (Millions of yen) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Americas | Europe | Asia | Other | Total |
| Overseas sales | 8,941 | 6,898 | 5,317 | 771 | 21,928 |
| Consolidated sales |  |  |  |  | 96,679 |
| Percentage of overseas sales to consolidated sales(\%) | 9.2 | 7.1 | 5.5 | 0.8 | 22.7 |

Note: 1. Overseas sales comprise sales of the Company and its consolidated subsidiaries in countries and regions other than Japan.
2. The major countries or regions in the respective divisions are as follows:

Americas: U.S.A., Venezuela and Colombia
Europe: Germany, Italy, Spain, France and Russia
Asia: China, Korea, Thailand and Vietnam


[^0]:    (Note) Percentage figures in the above tables indicate increase/decrease over the corresponding period of previous year.

[^1]:    (Note) Percentage figures in the above tables indicate increase/decrease over the corresponding period of previous year.

[^2]:    * The above estimates are based on information available on the date of this report's announcement. Actual results may differ from such estimates due to unforeseen circumstances.

